

The logo for RethinkALZ features the word "rethink" in a lowercase, sans-serif font with a red dot above the "i", and "ALZ" in a larger, bold, uppercase, sans-serif font. A horizontal line of colored squares (teal, purple, blue, yellow, red, green, yellow, teal, purple, teal) is positioned below the text.

rethinkALZ

JOIN A CLINICAL STUDY TO ADVANCE ALZHEIMER'S TREATMENT

PAVING THE WAY FOR FUTURE GENERATIONS

RethinkALZ Clinical Research Study

If you or a loved one has been diagnosed with Alzheimer's disease, or a physician suspects it may be Alzheimer's disease, you or they may be eligible to participate in a clinical research study. RethinkALZ is a new clinical trial for Alzheimer's disease. The purpose of this trial is to determine if a new, twice-a-day, oral drug candidate called simufilam is safe and effective in slowing down the progression of mild-to-moderate Alzheimer's disease. Simufilam is an investigational drug candidate that has not been approved by the United States Food and Drug Association (FDA), or any regulatory agency, for the treatment of any condition.

Study Criteria

To be considered for the RethinkALZ study, patients must:

- Be ages 50 to 87 years old
- Be diagnosed with, or have a suspected clinical diagnosis of, Alzheimer's disease
- Have a gradual change in memory for six months or more
- Have a family member or loved one who can be available as a study partner during the entire study
- Be fully vaccinated for COVID-19 or have had a previous COVID-19 infection

Other criteria will apply. There is no cost to the patient to participate in the RethinkALZ trial or for any of the study-related procedures. No hospitalization is required. You may be compensated for your time and travel for each clinical study appointment.

This study is actively enrolling.

For more information and to see if you or your loved one pre-qualifies, visit:

RethinkALZ.com or call 844-331-7300